Professor Georgina Long AO (Bluesky @gvlongphdmd)

Thrilled to announce Redefining Immunotherapy, a brand new vodcast series I’m hosting alongside 3 brilliant minds in medical oncology: Prof Alex Menzies, A/Profs Matteo Carlino & Ines da Silva. Ep 1 is LIVE now! Beyond the Tumour: Rethinking Cancer in the Immunotherapy Era. 25 min that might change how you think about it. 5 episodes – 1 released each week. Zero filter. youtu.be/WmKQmDmTWvY?si… via @YouTube #Melanoma #MedicalOncology #Immunotherapy #OncologyVodcast @MelanomaAus @Sydney_Uni @syd_health @Science_Academy @ausoftheyear @FulbrightAUS @AAHMS_health @MOGA_ORG

So great to see the @MelanomaAus team from around the world delivering important research results changing melanoma and cancer. @syd_health @Sydney_Uni @Science_Academy @AAHMS_health @FulbrightAUS @ausoftheyear

Fabulous #AACR2026 meeting, densely packed with science and research that will help us tackle the third space in cancer - those people who are still dying from it today. So pleased to present work in how we are tackling the third space at @MelanomaAus.

Honoured to deliver the 2026 Ann Moyal Lecture at the National Library of Australia last night. Breakthroughs don't come from certainty. They come from courage in the third space - the uncharted territory between what we know and what we must discover. That's where hope lives. That's where the work happens. Watch lecture> youtube.com/live/g7OVAegME… @MelanomaAus @Sydney_Uni @ausoftheyear @AAHMS_health @Science_Academy @FulbrightAUS @SydneyMedsoc

A warm welcome to the melanoma specialists of the future! #fellowship

Fabulous Sydney Sunday morning for Melanoma March 2026 - the 15th year of Australia-wide marches. Our goal is to cure more people with #melanoma by raising funds for critical research & clinical #trials, remember loved ones and those living with melanoma, and put ourselves at @MelanomaAus out of a job by raising awareness that most melanoma is preventable by following sun safety. I love a good swim, run, cycle, basketball game, swim at the beach, but we can do it safely: shade, clothing, hat, sunglasses, and sunscreen. Critically, drugs we develop in melanoma impact other #cancer. melanomamarch.org.au @Sydney_Uni @ausoftheyear @AAHMS_health @Science_Academy @FulbrightAUS @SydneyMedsoc

It’s time to bid farewell and say a huge thank you to our amazing 2025 @MelanomaAus Immuno-Oncology fellows – Dr Rubens Sperandio, Dr Julia Ressler and Dr Francis Proulx-Rocray. Over the past 12 months, as part of our MIA fellowship program, these three outstanding medical oncologists have worked hard alongside our Clinical Trials team and our advanced practice nurses, gaining experience in clinical research and immunotherapy treatment for melanoma and complex skin cancer patients. #fellowship #immunotherapy #oncology #melanoma

Proud to contribute my piece “The Weight of a Human Life” to the book of essays from Australians with ideas @theausinstitute “A Time for Bravery: What Happens when Australia Chooses Courage?”    I drew on my experience as a professor, medical leader, oncologist, and researcher working in the ‘Third Space’ - which is the unforgiving territory where patients are dying, existing drugs do not work, and hope drives action.   In this essay, I explore themes of action in uncertainty, giving real hope, and balancing ethical responsibility with experimental medicine. australiainstitute.org.au/store/a-time-f… @MelanomaAus @Sydney_Uni @ausoftheyear @Science_Academy @FulbrightAUS @AAHMS_health

Thrilled to celebrate three outstanding colleagues at @MelanomaAus! Huge congratulations to Professor Alex Menzies, Professor Sydney Ch’ng and Professor Serigne Lo on their well-deserved promotions to Professor at @sydney_uni. All exceptional researchers who are making a real difference in #melanoma research. @SerineLo #AlexMenzies @drsydneychng @Science_Academy @FulbrightAUS @AAHMS_health @ausoftheyear

Inspiring few days at the #ImmunotherapyBridge and #MelanomaBridge meetings in Naples 🇮🇹 Thank you to @PAscierto and @IstTumori for bringing together such brilliant minds! Highlight: the great debate with Christian Blank @NKI_nl on whether #neoadjuvant #immunotherapy in stage 2 melanoma is possible vs impossible. I had the privilege of arguing ‘possible’ - and the evidence is building! Also spoke on what drives me most: curing #cancer. We focused on the ‘Third Space’ - those patients who don’t respond to current immunotherapies - and how neoadjuvant approaches can help us crack this code. Our NeoIRENIE trial is designed to focus on just that. The path to curing more cancer is to understand and overcome resistance. This science matters. Finding a solution for these patients matters. Grazie Naples! 🇮🇹 #melanoma #clinicaltrials #cancerresearch @MelanomaAus @Sydney_Uni @ausoftheyear @Science_Academy @FulbrightAUS @AAHMS_health

The @NakedScientists podcast covers the biggest scientific breakthroughs and interviews with leading movers and shakers in science, technology and medicine. It’s created for everyone with an interest science, for all ages from 13 to 90. In the latest episode of the 'Titans of Science' series, @ProfGLongMIA AO uncovers what led her to her groundbreaking work in the treatment of melanoma, how #immunotherapy works, and what her current research and clinical efforts are focused on. Listen to this insightful podcast here > bit.ly/4poewBh

The Society for Melanoma Research (SMR) Annual Congress is underway in The Netherlands. As part of the SMR Congress, a Pathology Symposium has been held where MIA’s Rob Rawson and Mike Michael Taylor from @UCSF have presented on the International Neoadjuvant Melanoma Consortium pathology update. The MIA-led paper on this update has just been accepted in the Annals of Oncology journal. Over the coming days we will share exciting updates coming from SMR and the MIA team in attendance! @SocietyMelanoma #SMRCongress #MelanomaResearch #INMC

Honoured to present the 64th Lambie Dew Oration @Sydney_Uni ‘Courageous Medicine: From Evidence Users to Evidence Creators’. Thought provoking questions from medical students. I feel confident about the future of our medical workforce - people with compassion, reflection and passion to make the world a better place. People who will make the evidence to improve outcomes, not just use evidence that exists. Read essay adapted from my Lambie Dew Oration in @smh > smh.com.au/national/for-d… @SydneyMedsoc @MelanomaAus @ausoftheyear @FulbrightAUS @Science_Academy

Great to present at Tenmile’s FocalPoint 2025, a symposium during the #AusBiotech conference in Melbourne - all about ideas to improve #health and making them come alive. For me, it was about curing cancer by focusing on the ‘third space’ - those still dying of #melanoma for whom our standard #immunotherapy does not work. What we learn here we can apply to other #cancers. @MelanomaAus @Sydney_Uni @ausoftheyear

Please join me and other @MelanomaAus multidisciplinary experts at our specialist hybrid #symposium on Neoadjuvant Treatment, so we can ensure the recent PBS listings for #neoadjuvant regimens for Stage III melanoma translate into practice and ultimately better patient outcomes. This case-based hybrid symposium is designed to support clinicians in navigating this evolving treatment landscape. Through interactive discussion and expert commentary, we’ll explore how to select the right patients, choose between available regimens and clinical trials, time surgery appropriately, manage toxicities and ensure consistent pathological assessment.   On Monday evening 24 November (Sydney time) either in person at the Hyatt Regency Sydney, or online via zoom. See> events.humanitix.com/neoadjuvant-tr…

Melanoma Institute Australia Medical Director, Prof Georgina Long AO, was special guest this week on the Washington Post Live’s Chasing Cancer series, which explores the latest scientific advances driving the next wave of cancer breakthroughs. Prof Long explained the importance of neoadjuvant (pre-surgery) immunotherapy in cancer and melanoma, and detailed her passionate focus on the ‘third space’ - patients who don’t respond to single (anti-PD1) or dual checkpoint inhibitor immunotherapy – as she continues her lifework to cure cancer, save lives and give hope.   See full story > washingtonpost.com/washington-pos… (Prof Long interview starts at 29 mins). @ProfGLongMIA @washingtonpost @PostLive

Proud to lead this clinical trial MORPHEUS, comparing different neoadjuvant (pre-surgery) #immunotherapy combinations in stage III #melanoma. Shows how the neoadjuvant platform can deliver comparative clinical and translational data efficiently. anti-PD1+LAG3 and anti-PD1+CTLA4 are our most active combinations. TIGIT does not add. nature.com/articles/s4159… @MelanomaAus @ASCO @myESMO @Sydney_Uni @Science_Academy @ausoftheyear @FulbrightAUS